Journal
XENOBIOTICA
Volume 45, Issue 7, Pages 615-624Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/00498254.2014.1000430
Keywords
7-hydroxymethotrexate; Clinical; OAT1; OAT3; transporters
Categories
Funding
- Asahi Kasei Pharma Corporation
Ask authors/readers for more resources
1. Drug interaction potential between AK106-001616, a novel cytosolic phospholipase A(2) inhibitor, and methotrexate (MTX) in rheumatoid arthritis patients was investigated. This trial is registered with ClinicalTrials.gov, number NCT00902369. 2. In the clinical study, the 90% confidence intervals (CIs) for the geometric mean ratio (GMR) of AUC(0-t) of MTX administered after AK106-001616 200mg compared to the MTX without AK106-001616 were within 80-125%. However, administration of AK106-001616 at doses of 400 and 600mg exceeded the 125% threshold. As small but statistically significant increases in AUC(0-t) were observed, we investigated the mechanism for this drug-drug interaction between MTX and AK106-001616. 3. In vitro, AK106-001616 inhibited OAT1 (IC50 = 18.4 mu M, K-i = 33.6 mu M) in a non-competitive manner and OAT3 (IC50 = 1.80 mu M, K-i = 1.49 mu M) in a competitive manner. Both transporters are involved in MTX transport in renal proximal tubules. 4. AK106-001616 has a weak drug interaction with MTX. In vitro studies provide a mechanistic understanding of the in vivo inhibition of transporters by AK106-001616.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available